Is DSIP (Intranasal) safe during pregnancy or breastfeeding?

DSIP (Intranasal), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the mechanism of action of DSIP (Intranasal)?

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same DSIP molecule delivered intranasally. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

How does DSIP (Intranasal) interact with female hormonal cycling?

Cyclical hormone background influences how DSIP (Intranasal) is distributed, metabolised, and felt. Even where the compound's pharmacology is not directly hormonal, response often varies across follicular and luteal phases. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

What is the regulatory status of DSIP (Intranasal)?

DSIP (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What are the safety considerations for DSIP (Intranasal)?

Excellent tolerability. Mild nasal irritation possible. For female hormonal and cyclical use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. DSIP (Intranasal)'s Rapid CNS uptake via olfactory route pharmacokinetic profile and intranasal administration route influence the side-effect profile in predictable ways.

What should I look for in DSIP (Intranasal) sourcing and quality?

Acceptable DSIP (Intranasal) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 848 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ DSIP (Intranasal)

DSIP (Intranasal)

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: DSIP (Intranasal) is evaluated by women's-health clinicians on multiple axes. Same DSIP molecule delivered intranasally The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions.. The compound's neuropeptide (sleep, intranasal) pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

Cycle SupportAutoimmune SupportLibido (Female)Bone DensityBody Composition (Female)

Key Takeaways

Female-physiology lens: DSIP (Intranasal) response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Same DSIP molecule delivered intranasally.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 100-300 mcg 1 spray before sleep via intranasal; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. DSIP (Intranasal)'s contribution to each varies; the subsections below work through these in turn.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, DSIP (Intranasal) is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. DSIP (Intranasal)'s effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Fertility and reproductive considerations

DSIP (Intranasal)'s effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Endometriosis Support

For endometriosis support in female users, DSIP (Intranasal) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Libido (Female)

Libido (Female) is one of the dimensions on which women track DSIP (Intranasal) response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Bone Density

In the perimenopausal window, DSIP (Intranasal) for bone density produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Fertility

For fertility in female users, DSIP (Intranasal) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	60-300 mcg	4–6 weeks initial cycle
Women's Health focus	Intranasal	100-300 mcg	1 spray before sleep
Maintenance phase	Intranasal	70-300 mcg	Ongoing with periodic pauses

Dose timing for DSIP (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

DSIP (Intranasal) + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with DSIP (Intranasal)'s mechanism in female physiology protocols.
DSIP (Intranasal) + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with DSIP (Intranasal)'s mechanism in female physiology protocols.
DSIP (Intranasal) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with DSIP (Intranasal)'s mechanism in female physiology protocols.
DSIP (Intranasal) + Epithalon: Identified by Khavinson in St. Pairs naturally with DSIP (Intranasal)'s mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical

Excellent tolerability. Mild nasal irritation possible.

Lens-specific safety considerations for female physiology use of DSIP (Intranasal): Excellent tolerability. Mild nasal irritation possible. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

DSIP (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
DSIP (Intranasal)	Neuropeptide (sleep, intranasal)	Rapid CNS uptake via olfactory route	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Can I use DSIP (Intranasal) alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Can I use DSIP (Intranasal) during pregnancy or while trying to conceive?

Most peptide therapeutics, including DSIP (Intranasal), do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Is DSIP (Intranasal) appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

What is DSIP (Intranasal)?

DSIP (Intranasal) (also known as Delta Sleep-Inducing Peptide — Nasal) is a 9-residue neuropeptide (sleep, intranasal) with a molecular weight of 848 Da and a plasma half-life of Rapid CNS uptake via olfactory route. Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The compound is studied primarily in the female physiology domain for the applications outlined above.

What route should I use for DSIP (Intranasal)?

DSIP (Intranasal) is delivered by intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Clinical Protocol

Start a DSIP (Intranasal) Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified DSIP (Intranasal) and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: Rapid CNS uptake via olfactory route
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for DSIP (Intranasal)

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised